Press Releases

HOUSTON, Nov. 20, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced Chief Executive Officer of CNS Pharmaceuticals, John M. Climaco, along with founder, Waldemar Priebe, P

Relationship brings to life United Imaging's vision, commitment to increased access to medical imaging HOUSTON, Nov. 20, 2019 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, today announced a strategic collaboration with Shared Medical Services (SMS) to be the first in the U.S. to launc

CHICAGO, Nov. 20, 2019 /PRNewswire/ -- Ambetter from IlliniCare Health, underwritten by Celtic Insurance Company, is expanding its provider network in Cook and DuPage counties for its Health Insurance Marketplace product. On November 1, 2019, AMITA Health joined the

GUELPH, ON, Nov. 20, 2019 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced results for the three and nine-month periods ended September 30, 2019. Biorem's complete 2019 third quarter financial statements and MD&A have been filed on SEDAR (

NEW YORK, Nov. 20, 2019 /PRNewswire/ -- Clayton, Dubilier & Rice today announced an agreement under which CD&R-managed funds will acquire Cynosure, LLC, a leader in medical aesthetics systems and technologies, from Hologic, Inc. (NASDAQ:HOLX).

NEW YORK, Nov. 20, 2019 /PRNewswire/ -- Gene Food, Inc., a New York City based nutrigenetics startup has launched a proprietary algorithm that divides people int

NEW YORK, Nov. 20, 2019 /PRNewswire/ -- Pharma artificial intelligence pioneer tellic today announced the creation of its advisory board to provide external strategic review of and expert advice to the company's management with regards to drug360 graph, tellic's new knowledge graph software as a service offering. The advisory board will cover critical areas of tellic's k

CEDAR KNOLLS, N.J., Nov. 20, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin, a proprietary bioactive composition made from fertilized egg yolk that helps build lean muscle, announced today that an abstract based on the results from a clinical trial evaluating the impac

PITTSBURGH, Nov. 20, 2019 /PRNewswire/ -- Industrial companies now have access to a streamlined, holistic, end-to-end solution for design, automation, production and lifecycle management, thanks to a new strategic partnership between

- MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen -- Targeting enrollment of 180 symptomatic and anemic patients previously treated with a JAK inhibitor –- Top-line data anticipated in Q4 2021 - VANCOUVER, Nov. 20, 2019 /PRNew